Pantoprazole Sodium Delayed Release

PANTOPRAZOLE SODIUM DELAYED RELEASE- pantoprazole sodium tablet, delayed release
Northwind Pharmaceuticals

NDC: 51655-500-52

MFG: 0378-6689-10

Pantoprazole Sodium Delayed Release 40 MG

30 Tablets

Rx only


Exp. Date:

Each film-coated tabler contains: pantoprazole sodium, USP equivalent to 40 mg of pantoprazole

Dosage: See package insert

Store at 66-77 degrees F.

Store in a tight, light-resistant container (See USP). Keep out of the reach of children.

Mfg for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 USA Made in India Lot#:

Repackaged by: Northwind Pharmaceuticals, Indianapolis, IN 46256

Pantoprazole 51655-500
(click image for full-size original)

Indications and Usage

Pantoprazole is a proton pump inhibitor indicated for the following:

•Short-term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD).

•Maintenance of Healing of Erosive Esophagitis.

•Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.

Warnings and Precautions

•Symptomatic response does not preclude presence of gastric malignancy.

•Atrophic gastritis has been noted with long-term therapy.

•PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.

•Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine.

•Hypomagnesemia has been reported rarely with prolonged treatment with PPIs

Adverse Reactions

The most frequently occurring adverse reactions are as follows:

•For adult use (> 2%) are headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia.

To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or

Drug Interactions

•Do not coadminister with atazanavir or nelfinavir.

•Concomitant warfarin use may require monitoring.

•May interfere with the absorption of drugs where gastric pH is important for bioavailability.

•May produce false-positive urine screen for THC.

•Methotrexate: Pantoprazole may increase serum level of methotrexate

Information describing use in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc.’s pantoprazole sodium delayed-release tablets. However, due to Wyeth Pharmaceuticals Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

pantoprazole sodium delayed release tablet, delayed release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:51655-500(NDC:0378-6689)
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Product Characteristics
Color yellow Score no score
Shape OVAL Size 11mm
Flavor Imprint Code M;P9
# Item Code Package Description Multilevel Packaging
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA090970 03/21/2014
Labeler — Northwind Pharmaceuticals (036986393)
Registrant — Northwind Pharmaceuticals (036986393)
Name Address ID/FEI Operations
Northwind Pharmaceuticals 036986393 repack (51655-500)

Revised: 06/2014 Northwind Pharmaceuticals

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.